Oral Tranexamic Acid Enhances the Efficacy of Low‐Fluence 1064‐Nm Quality‐Switched Neodymium‐Doped Yttrium Aluminum Garnet Laser Treatment for Melasma in Koreans: A Randomized, Prospective Trial. Issue 3 (26th December 2012)

• Record Type: Journal Article
• Authors: Shin, Jung U; Park, Jihun; Oh, Sang Ho; Lee, Ju Hee
• Is Part Of: Dermatologic surgery. Volume 39:Issue 3(2015:Jan.)Part 1
• Page Start: 435
• Page End: 442
• Publication Date: 2012-12-26
• Subjects: Skin -- Surgery -- Periodicals; Skin -- Diseases -- Surgery -- Periodicals; 617.477
• DOI: 10.1111/dsu.12060
• Languages: English
• ISSNs: 1076-0512

Abstract

Abstract : Background: Tranexamic acid (TA) has recently gained in popularity in the treatment of pigmentary disorders. Objective: To evaluate the clinical efficacy and safety of oral TA combined with low‐fluence 1064‐nm quality‐switched neodymium‐doped yttrium aluminum garnet (QSNY) laser for the treatment of melasma. Materials and methods: Forty‐eight patients with melasma were enrolled in the study and subsequently divided into two groups: a combination group and a laser treatment group. All patients were treated with two sessions of low‐fluence QSNY laser, and patients in the combination group took 8 weeks of oral TA. Two blinded dermatologists evaluated patients using the Modified Melasma Area and Severity Index (mMASI) and a clinical improvement scale. Results: Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from base line. Based on overall clinical improvement, a greater number of patients scored as grade 3 and more in the combination group; no patients were scored as grade 4 in the laser‐alone group. Conclusions: Oral TA may prove a safe and efficient treatment option for melasma in combination with low‐fluence QSNY laser therapy.